Orchid Pharma Appoints Arjun Dhanuka as Whole-Time Director, Schedules 33rd AGM
Orchid Pharma's Board meeting on Sept 3, 2026, approved appointing M/s. J Karthikeyan & Associates as Cost Auditors for FY27. Mr. Arjun Dhanuka was appointed Whole-Time Director for five years. The 33rd AGM is scheduled for Sept 29, 2026, with cut-off dates for notice and e-voting set.
The appointment of a Whole-Time Director and the scheduling of the AGM are significant corporate governance events. The appointment of a new director can influence future strategy and operations, thus having a medium-term impact on the company.
The announcement details routine corporate actions like board meetings, auditor appointments, and AGM scheduling, with the appointment of a new Whole-Time Director being the most significant event. While positive for the company's governance, it does not immediately impact financial performance, hence neutral.
Orchid Pharma Limited announced the outcome of its Board Meeting held on September 03, 2026. The board has approved the appointment and remuneration of the company's Cost Auditors for the Financial Year 2026-27, with M/s. J Karthikeyan & Associates being appointed, subject to member ratification at the ensuing AGM.
Furthermore, Mr. Arjun Dhanuka (DIN: 00454689) has been appointed as Whole-Time Director for a tenure from September 03, 2026, to September 02, 2031. Mr. Dhanuka brings over a decade of experience in the pharmaceutical sector, having previously served in key roles at Dhanuka Laboratories Limited and Synmedic Laboratories.
The Board also approved the notice for the 33rd Annual General Meeting (AGM) of the Company, scheduled for September 29, 2026. The cut-off date for determining shareholders eligible to receive the AGM notice is September 04, 2026, and the cut-off date for e-voting eligibility is September 22, 2026. The remote e-voting period will run from September 26, 2026, to September 28, 2026. An e-voting agency and a scrutinizer have also been appointed to facilitate the voting process.
A plain-language summary of a public exchange filing by Orchid Pharma Limited. Read the original for the full detail.